Trial Profile
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab-Paclitaxel (Abraxane) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2020
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Necitumumab (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 17 Nov 2019 Status changed from active, no longer recruiting to completed.
- 16 Jul 2019 Planned End Date changed from 17 Jun 2019 to 17 Dec 2019.
- 18 Jan 2019 Planned End Date changed from 17 Dec 2018 to 17 Jun 2019.